Search the Newsreel

CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?

CareDx (CDNA) shares rallied 35.6% due to investor optimism following the finalization of Medicare Local Coverage Determination (LCD) for molecular testing related to solid organ allograft rejection. This policy ensures coverage for CareDx's transplant surveillance offerings in kidney, heart, and lung. While the company …

Price to earnings forward of CareDx, Inc. – GETTEX:1K9

The article focuses on the "Price to earnings forward" financial metric for CareDx, Inc. (1K9) on the Gettex exchange. It appears to be a financial data point provided by TradingView, without additional analysis or detailed financial reporting.

CAREDX INC : BTIG RAISES TARGET PRICE TO $45 FROM $28

BTIG has raised its target price for CAREDX INC (CDNA.O) to $45 from the previous $28. This update was reported by Reuters on July 17, 2026. The information presented reflects the author's opinion and is not intended as investment advice.

CareDx says final Medicare LCD maintains coverage for transplant rejection surveillance tests

CareDx announced that Medicare has finalized a Local Coverage Determination (LCD) that continues to support molecular surveillance testing for solid organ transplant rejection. The policy maintains coverage for kidney, heart, and lung offerings, establishing frequency limits for the first three years post-transplant while keeping …

Why Is CareDx Stock Skyrocketing Thursday?

CareDx (NASDAQ: CDNA) stock is skyrocketing after Medicare finalized its Local Coverage Determination (LCD) for molecular testing to monitor solid organ transplant rejection. This policy affirms continued Medicare coverage for CareDx's transplant surveillance portfolio, including testing for kidney, heart, and lung transplants. The company's …

GeneDx Holdings Corp. (WGS) Faces Class Action Lawsuit Over Misleading Statements

GeneDx Holdings Corp. (WGS) is facing a class action lawsuit alleging misleading statements regarding its acquisition of Fabric Genomics. The lawsuit claims executives concealed critical issues with Fabric's viability, leading to inflated stock prices before a significant drop following disappointing Q1 2026 results. Despite …

GeneDx Shareholder Alert: ClaimsFiler Reminds Investors

ClaimsFiler is reminding investors who suffered losses exceeding $100,000 in GeneDx Holdings Corp. (NasdaqGS: WGS) to file as lead plaintiffs in a securities class action lawsuit by August 3, 2026. The lawsuit alleges that GeneDx and its executives failed to disclose material information during …

CareDx to report Q2 2026 financial results on July 30

CareDx, Inc. announced it will release its second-quarter 2026 financial results after market close on July 30, 2026. The company will host a conference call on the same day at 4:30 p.m. ET to discuss its performance. CareDx specializes in precision medicine diagnostics for …

GeneDx Holdings Corp. Class Action Reminder – Robbins LLP Encourages WGS Investors to Contact the Firm for Information About Their Rights

Robbins LLP is reminding investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a class action lawsuit filed against the company. The lawsuit alleges that GeneDx misled investors regarding the positive financial impact of its acquisition of Fabric Genomics, an AI-driven genomic interpretation company. Following …

WGS DEADLINE: SueWallSt Reminds GeneDx Holdings Corp. Investors of Upcoming Securities Class Action Deadline

SueWallSt.com is reminding investors of GeneDx Holdings Corp. (NASDAQ: WGS) about an upcoming securities class action deadline of August 3, 2026. The lawsuit names CEO Katherine Stueland and CFO Kevin Feeley as individual defendants, alleging they were aware of significant problems with the Fabric …

Caredx Inc stock hits 52-week high at 36.4 USD By Investing.com

CareDx Inc.'s stock reached a new 52-week high of $36.4, marking a 151.91% increase over the past year, driven by strong investor confidence and positive market response. Despite being potentially overvalued according to InvestingPro analysis, the company boasts "GREAT" financial health and 19% revenue …

WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Levi & Korsinsky, LLP has announced a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for investors who suffered losses between April 16, 2025, and May 4, 2026. This action follows a significant decline in WGS shares after the company disclosed a …

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

CareDx announced the finalization of the Medicare Local Coverage Determination (LCD) for molecular testing in solid organ allograft rejection, affirming coverage for its transplant surveillance offerings in kidney, heart, and lung. This policy ensures continued coverage for their AlloSure and AlloMap tests, crucial for …

GeneDx Holdings Corp. Class Action Lawsuit Seeks Recovery

Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for investors who purchased stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made misleading statements regarding the viability of …

MDXG Forecast — Price Target — Prediction for 2027

MDXG Q1 2026 Earnings: EPS Miss Widens Losses, Stock Slips on Surprise - New Analyst Coverage

GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - Hagens Berman

GeneDx Holdings Corp. (WGS) Securities Fraud Investigation - Levi & Korsinsky

EDX Medical Group plc share price, company news, analysis and interviews

GeneDx Holdings Corp. (NASDAQ:WGS) Analysts Just Slashed This Year's Revenue Estimates By 12%

MiMedx: The Hard Math Behind My Downgrade To Hold

Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings

Does GeneDx’s Guidance Cut And Core Shift Reshape The Bull Case For GeneDx Holdings (WGS)?

Rare-disease test volumes rose 34%, but GeneDx cut 2026 forecast

Earnings call transcript: GeneDx Q1 2026 misses earnings, stock rises slightly

Mizuho cuts MiMedx stock price target on weak wound sales

Earnings call transcript: MiMedx Q1 2026 results miss forecasts, stock dips

MiMedx: Q1 Earnings Snapshot

MIMEDX Announces First Quarter 2026 Operating & Financial Results

MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates

Earnings Preview: MiMedx (MDXG) Q1 Earnings Expected to Decline

How The MiMedx Group (MDXG) Story Is Shifting With Medicare And Analyst Revisions

GeneDx Holdings Corp. (NASDAQ:WGS) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings

EDX Medical reports interim progress with revenue growth expected from diagnostics pipeline

What date does MiMedx Group's (MDXG) report Earnings - Earnings Calendar & Announcement